Felix Gronau1, Maximilian Jara1, Linda Feldbrügge1, Vincent Wolf1, Alan Oeff1, Beate Rau2,3. 1. Chirurgische Klinik Campus Charité Mitte | Campus Virchow Klinikum, Charité Universitätsmedizin, Berlin, Deutschland. 2. Chirurgische Klinik Campus Charité Mitte | Campus Virchow Klinikum, Charité Universitätsmedizin, Berlin, Deutschland. beate.rau@charite.de. 3. Klinik für Chirurgie, Universitätsmedizin Berlin, Charité Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Deutschland. beate.rau@charite.de.
Abstract
BACKGROUND: Gastric cancer with peritoneal metastases is associated with an extremely poor prognosis. Developed multimodal treatment concepts, which include a combination of perioperative systemic treatment and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), show promising results with respect to improvement of the long-term survival. METHODS: This article contains a review of the literature of published studies on the topic of gastric cancer and peritoneal metastasis. RESULTS: The prognosis of patients with gastric cancer peritoneal carcinomatosis shows an extremely limited median survival of 7 months under palliative second-line systemic treatment. The median survival time increased to 12 months with cytoreductive surgery and in combination with HIPEC showed a positive effect on survival in individual studies. EXPERT OPINION: Treatment recommendations for patients with peritoneal metastases of gastric cancer should be carried out by experts in surgical reference centers.
BACKGROUND: Gastric cancer with peritoneal metastases is associated with an extremely poor prognosis. Developed multimodal treatment concepts, which include a combination of perioperative systemic treatment and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), show promising results with respect to improvement of the long-term survival. METHODS: This article contains a review of the literature of published studies on the topic of gastric cancer and peritoneal metastasis. RESULTS: The prognosis of patients with gastric cancer peritoneal carcinomatosis shows an extremely limited median survival of 7 months under palliative second-line systemic treatment. The median survival time increased to 12 months with cytoreductive surgery and in combination with HIPEC showed a positive effect on survival in individual studies. EXPERT OPINION: Treatment recommendations for patients with peritoneal metastases of gastric cancer should be carried out by experts in surgical reference centers.
Authors: Y Yonemura; E Canbay; Y Li; F Coccolini; O Glehen; P H Sugarbaker; D Morris; B Moran; S Gonzaletz-Moreno; M Deraco; P Piso; D Elias; D Batlett; H Ishibashi; A Mizumoto; V Verwaal; H Mahtem Journal: Eur J Surg Oncol Date: 2016-04-09 Impact factor: 4.424
Authors: Markus Moehler; Salah-Edin Al-Batran; Tilo Andus; Jann Arends; Dirk Arnold; Gustavo Baretton; Jan Bornschein; Wilfried Budach; Severin Daum; Christoph Dietrich; Matthias Ebert; Wolfgang Fischbach; Michael Flentje; Ines Gockel; Lars Grenacher; Jörg Haier; Stefan Höcht; Rolf Jakobs; Christian Jenssen; Barbara Kade; Stefan Kanzler; Jost Langhorst; Hartmut Link; Florian Lordick; Dietmar Lorenz; Sylvie Lorenzen; Manfred Lutz; Helmut Messmann; Hans-Joachim Meyer; Stefan Mönig; Katja Ott; Michael Quante; Christoph Röcken; Peter Schlattmann; Wolff-H Schmiegel; Andreas Schreyer; Andrea Tannapfel; Peter Thuss-Patience; Arved Weimann; Susanne Unverzagt Journal: Z Gastroenterol Date: 2019-12-11 Impact factor: 2.000
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702